ASCENDIS PHARMA A/S - ADR (ASND) Stock Price & Overview
NASDAQ:ASND • US04351P1012
Current stock price
The current stock price of ASND is 218.06 USD. Today ASND is down by -1.72%. In the past month the price decreased by -7.19%. In the past year, price increased by 40.97%.
ASND Key Statistics
- Market Cap
- 13.191B
- P/E
- N/A
- Fwd P/E
- 39.18
- EPS (TTM)
- -4.37
- Dividend Yield
- N/A
ASND Stock Performance
ASND Stock Chart
ASND Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 83.8% of all stocks.
ASND Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ASND. ASND has a bad profitability rating. Also its financial health evaluation is rather negative.
ASND Earnings
On February 11, 2026 ASND reported an EPS of -0.55 and a revenue of 247.50M. The company missed EPS expectations (-1098.26% surprise) and missed revenue expectations (-1.48% surprise).
ASND Forecast & Estimates
24 analysts have analysed ASND and the average price target is 289.23 USD. This implies a price increase of 32.64% is expected in the next year compared to the current price of 218.06.
For the next year, analysts expect an EPS growth of 227.33% and a revenue growth 96.07% for ASND
ASND Groups
Sector & Classification
ASND Financial Highlights
Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -4.37. The EPS increased by 42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ASND Ownership
ASND Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 362.351B | ||
| AMGN | AMGEN INC | 15.32 | 188.551B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 170.497B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.28 | 114.627B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 77.866B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.1 | 40.669B | ||
| INSM | INSMED INC | N/A | 31.035B | ||
| NTRA | NATERA INC | N/A | 28.359B | ||
| BIIB | BIOGEN INC | 11.42 | 26.951B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 22.845B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.149B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ASND
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
IPO: 2015-01-28
ASCENDIS PHARMA A/S - ADR
Tuborg Boulevard 12
Hellerup 2900 DK
CEO: Jan Moller Mikkelsen
Employees: 1017
Phone: 4570222244
ASCENDIS PHARMA A/S - ADR / ASND FAQ
Can you describe the business of ASCENDIS PHARMA A/S - ADR?
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
What is the current price of ASND stock?
The current stock price of ASND is 218.06 USD. The price decreased by -1.72% in the last trading session.
Does ASND stock pay dividends?
ASND does not pay a dividend.
What is the ChartMill technical and fundamental rating of ASND stock?
ASND has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for ASND stock?
24 analysts have analysed ASND and the average price target is 289.23 USD. This implies a price increase of 32.64% is expected in the next year compared to the current price of 218.06.
Can you provide the number of employees for ASCENDIS PHARMA A/S - ADR?
ASCENDIS PHARMA A/S - ADR (ASND) currently has 1017 employees.
What is the outstanding short interest for ASCENDIS PHARMA A/S - ADR?
The outstanding short interest for ASCENDIS PHARMA A/S - ADR (ASND) is 6.6% of its float.